Monoiodobenzoic acid compounds and their application in anti-adv7 virus

A technology of iodobenzoic acid and iodobenzoic acid, which is applied in the direction of antiviral agents, medical preparations containing active ingredients, and pharmaceutical formulas, can solve the problems of unreported inhibitory activity, and achieve easy large-scale production promotion and synthesis Simple process, economical and fast effect

Active Publication Date: 2022-08-05
HUBEI UNIV OF TECH
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the antiviral activity of iodocarboxylic acids, including the inhibitory activity against ADV7 virus, has not been reported so far.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Monoiodobenzoic acid compounds and their application in anti-adv7 virus
  • Monoiodobenzoic acid compounds and their application in anti-adv7 virus
  • Monoiodobenzoic acid compounds and their application in anti-adv7 virus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] [Example 1] Experiment on anti-ADV7 activity of monoiodobenzoic acid compounds L1-L3

[0031] In the present embodiment, the anti-ADV7 activity research experiment was carried out on the above-mentioned compounds, and the experimental conditions are as follows:

[0032] 1. Test content:

[0033] Analysis of compound anti-ADV7 activity: the present invention will evaluate the anti-ADV7 activity of monoiodobenzoic acid by combining cytopathic effect analysis and MTT assay cell survival rate detection method.

[0034] 2. Test method:

[0035] 2.1.1 Toxicity of compounds to host Hela cells

[0036] Plate HeLa cells in 96-well plates at 37°C, 5% CO 2 After the incubator was full of monolayers, the cell culture medium was discarded, and cell maintenance solutions containing different concentrations of test compounds were added to continue the culture. SPSS 11.5 software was used to calculate the Median cyctoxic concentration (CC50) of the drug to cells. Cell viability = ...

Embodiment 2

[0048] [Example 2] Inhibitory effect test of monoiodobenzoic acid compounds L1 and L3 on the production of ADV7 progeny virus

[0049] In the present embodiment, monoiodobenzoic acid has been carried out in-depth research on anti-ADV7 activity, and the inhibitory effect test of compounds L1 and L3 on the production of ADV7 progeny virus has been carried out. The test conditions are as follows:

[0050] 1. Test content

[0051] The inhibitory effects of compounds L1 and L3 on the virus production of ADV7 progeny were detected after ADV7 infection of Hela cells.

[0052] 2. Test method

[0053] HeLa cells in logarithmic growth phase were plated in 24-well plates, 100 TCID after confluent monolayer 50 ADV7-infected cells, incubated at 37°C for 1.5 h, removed the virus solution, washed three times with PBS, and added a cell maintenance solution containing 25 μg / mL L1 and 50 μg / mL L3. Cells and supernatant culture medium were collected after 48h, and after three freeze-thaw lysi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a monoiodobenzoic acid compound and its application in anti-ADV7 virus. Through the mono-iodobenzoic acid (L1), meta-iodobenzoic acid (L2), p-iodobenzoic acid (L3) anti-ADV7 activity research experiments, compounds L1, L3 inhibit the cells produced by ADV7 on the host cell Hela Pathogenic effect (CPE), enhance cell survival rate, reduce progeny virus production, and can be used in the preparation of anti-ADV7 virus drugs.

Description

technical field [0001] The invention relates to the technical field of antiviral drugs, in particular to a monoiodobenzoic acid compound and its application in anti-ADV7 virus. Background technique [0002] Adenovirus (adenovirus, ADV) is a group of widely distributed DNA viruses. There are 52 known species of adenoviruses, named ADV1-ADV52, which are divided into two genera and more than 100 serotypes in total. About one-third of the known serotypes of human adenoviruses are associated with human disease. Adenovirus can invade various tissues and organs such as respiratory tract, eye conjunctiva, gastrointestinal tract and urinary tract, mainly respiratory tract infection. In severe cases, it can cause pneumonia in children and accumulate in various systems of the body. Adenoviral pneumonia caused by adenovirus infection is one of the most serious types of pneumonia in children. The adenovirus types associated with respiratory diseases mainly include ADV7, ADV3 and ADV4,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/192A61P31/14
CPCA61K31/192A61P31/14
Inventor 王龙胜王悦魏艳红李妮朱茂春郭超袁子月冯治坤
Owner HUBEI UNIV OF TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap